About: Verucerfont

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.

Property Value
dbo:abstract
  • Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. It is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. It has shown promising results in animal studies. However, human trials have shown that while the neuroendocrine effects translate from animal models, the alcohol anti-craving effects do not. (en)
dbo:casNumber
  • 885220-61-1
dbo:fdaUniiCode
  • X60608B091
dbo:kegg
  • D09695
dbo:pubchem
  • 11596613
dbo:thumbnail
dbo:wikiPageID
  • 44745250 (xsd:integer)
dbo:wikiPageLength
  • 3031 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1073190168 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:c
  • 22 (xsd:integer)
dbp:casNumber
  • 885220 (xsd:integer)
dbp:chemspiderid
  • 28295024 (xsd:integer)
dbp:h
  • 26 (xsd:integer)
dbp:iupacName
  • 3 (xsd:integer)
dbp:kegg
  • D09695 (en)
dbp:n
  • 6 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 11596613 (xsd:integer)
dbp:routesOfAdministration
  • Oral (en)
dbp:smiles
  • CC[C@@H]Nc2ccC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • NZQAFTPOKINLRY-KRWDZBQOSA-N (en)
dbp:unii
  • X60608B091 (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. (en)
rdfs:label
  • Verucerfont (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License